Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Total Current Assets
All assets expected to be converted to cash or used up within one year.
Entera Bio Ltd.NASDAQ: ENTX
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets falls 41.1% from a year ago
Total current assets stood at $12.49M at the end of Q1 FY2026, down 41.1% from a year earlier and up 75.8% from the prior quarter. Over 3 fiscal years it compounded at -17.9% a year.
Context
- Total current assets amounted to 95.2% of total assets at the end of Q1 FY2026, down 3.1 pp from a year earlier.
- Total current assets increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps falling in the next quarterly balance sheet after a -41.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 7.11M USD
- Year-over-year change
- -20.8%
- 4-year CAGR
- -27.2%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.11M | -20.8% |
| FY2024 | 2024-12-31 | 8.97M | -20.3% |
| FY2023 | 2023-12-31 | 11.26M | -12.4% |
| FY2022 | 2022-12-31 | 12.85M | -49.3% |
| FY2021 | 2021-12-31 | 25.33M | — |
Total Current Assets vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's Mar 2026 total current assets of $12.49M is the 9th highest of the 10 companies compared; the peer median is $57.61M.
- Its year-over-year change of -41.1% is the 7th highest of 10, against a peer median of -22.9%.
- Total current assets amounts to 95.2% of total assets for ENTX, versus a peer median of 79.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $181.59M | -28.9% | -22.6% | 66.7% | |
| Mar 2026 | $133.09M | -14.1% | -12.2% | 99.6% | |
| Mar 2026 | $95.28M | +311.8% | -14.5% | 51.1% | |
IRDOpus Genetics, Inc. | Mar 2026 | $66.6M | +39.0% | +0.7% | 99.7% |
| Mar 2026 | $57.61M | -22.9% | -14.9% | 97.6% | |
| Mar 2026 | $39.44M | -45.1% | -42.1% | 79.2% | |
| Mar 2026 | $31.84M | -51.8% | -36.7% | 27.1% | |
| Apr 2026 | $14.69M | -12.4% | -19.3% | 98.8% | |
| Mar 2026 | $12.49M | -41.1% | -17.9% | 95.2% | |
| Mar 2026 | $6.98M | -51.3% | -32.1% | 23.5% | |
| Peer median (excluding ENTX) | $57.61M | -22.9% | -19.3% | 79.2% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.